Spondyloarthritis & psoriatic arthritis

Sex Differences in the Effectiveness of First‐Line Tumor Necrosis Factor Inhibitors in Psoriatic Arthritis: Results From the European Spondyloarthritis Research Collaboration Network

Arthritis RheumatolPublished Observational cohort study

Authors' conclusion

Despite comparable disease characteristics at baseline, women with PsA have reduced treatment response and retention rates to their first TNFi

Study context

Population
Patients with psoriatic arthritis (PsA) starting their first tumor necrosis factor inhibitor (TNFi) across 13 European Spondyloarthritis Research Collaboration Network registries50% women
Participants
7,679 patients
Exposure
Women vs men with PsA initiating first TNFi
Outcome
Low disease activity (LDA) by DAS28-CRP (<3.2)
Follow-up
6 months
Methodological detailspooled registry data, 13 European registries pooled, logistic regression adjusted for age, country, csDMARD treatment and TNFi start year, Kaplan-Meier estimator
  • Pooled registry data
  • 13 European registries pooled
  • Logistic regression adjusted for age, country, csDMARD treatment and TNFi start year
  • Kaplan-Meier estimator

Main finding

As reported in the abstract

LDA (DAS28-CRP <3.2)
Women vs MenRelative risk (95% CI)
Unadjusted
0.82(0.80–0.84)
Adjusted
0.83(0.81–0.85)

Observational data: associations, not effects.

Further findings

OutcomeWomenMen
TNFi retention rate, 6 / 12 / 24 months (n = 17,842)79%, 64%, and 50%88%, 77%, and 64%
Baseline DAS28-CRPMean4.4 (SD 1.2)4.2 (SD 1.2)

TNFi retention rate, 6 / 12 / 24 months (n = 17,842)

Women had significantly lower retention rates than men at all time points

Baseline DAS28-CRP

Patient-reported outcome measures were worse in women

Original publication

Sex Differences in the Effectiveness of First‐Line Tumor Necrosis Factor Inhibitors in Psoriatic Arthritis: Results From the European Spondyloarthritis Research Collaboration Network. Arthritis Rheumatol. Published 25 February 2024. doi:10.1002/art.42758

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.